Navigation Links
Elekta to Highlight Clinical and Safety Advantages of Gamma Knife Radiosurgery at 2013 AANS Meeting

NEW ORLEANS, April 25, 2013 /PRNewswire/ -- At the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting April 27-May 1 at the Ernest N. Morial Convention Center, Elekta (booth #2239) will spotlight the continuing preeminence of Gamma Knife® stereotactic radiosurgery (SRS) as the gold standard for treating benign and malignant brain tumors, plus other functional and vascular brain disorders.

"As the only radiosurgery device designed and dedicated to the brain, Leksell Gamma Knife has set the standard of safe and effective treatment of brain conditions," says Jay Hoey , Executive Vice President, Elekta North America . "Today, it remains the standard by which all other radiosurgery treatments are measured, treating more than 70,000 people a year with more than 800 scientific papers [studies with more than 30 patients] backing the technology.

"Gamma Knife surgery is an exceptional treatment choice for cases in which adjacent critical structures are at high risk of radiotoxicity, such as in the treatment of trigeminal neuralgia, residual meningiomas and acoustic neuroma," he adds. "For other intracranial targets such as multiple brain metastases, Leksell Gamma Knife provides less dose to normal brain tissues than other techniques."

Spotlight on patient safety and provider efficiency
Dedicated to intracranial stereotactic radiosurgery, Leksell Gamma Knife supports enhanced patient safety via the system's single-focused SRS design and simplicity-of-operation, which decrease the risk of mechanical and human error.

Typically capable of completing therapy in a single outpatient procedure, Gamma Knife surgery has also demonstrated significant efficiency advantages for providers as well. In comparison, Center for Medicare Services (CMS) 2011 claims data indicate that most patients receiving SRS delivered with a linear-accelerator require up to four outpatient procedures to complete their course of therapy.

Gamma Knife also will be featured in the Scientific Program of the AANS with results from two multicenter trials detailing the results of Gamma Knife in the treatment of benign tumors and hemangioblastomas, and two single center, large series reports on the use of Gamma Knife in vascular malformations. In addition, Gamma Knife is featured in several breakfast seminars and practical clinics, which will further clarify the role of the technology as an important adjunct to neurosurgery.

Additional Elekta solutions to be showcased at AANS include:

  • Leksell GammaPlan® 10, for optimal treatment planning for Gamma Knife radiosurgery
  • Elekta Neuromag® TRIUX, the most sophisticated magnetoencephalography (MEG) system available
  • Leksell Stereotactic System®, the preferred system for functional neurosurgery and biopsies
  • Leksell SurgiPlan® 10, for advanced, image-based neurosurgical planning

For further information, please contact:
Johan Andersson , Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, email:  
Time zone: CET: Central European Time 

Michelle Joiner , Director, Global Public Relations and Brand Management, Elekta 
Tel: +1 770-670-2447, email: 
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives. 

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website:

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta and Philips Research Consortium on MRI-Guided Radiation Therapy Adds The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
2. MD Anderson Cancer Center Acquires Two Elekta Versa HD Systems
3. Nucletron, an Elekta company, to Debut New Flexitron Brachytherapy Afterloading Platform at 2013 American Brachytherapy Society Meeting
4. New Versa HD System Tops Elektas Comprehensive Array of Cancer Management Solutions at 2nd ESTRO Forum
5. U.K. Clinic Anticipating New Era of Radiotherapy Speed and Precision with Elektas New Versa HD System
6. Elektas Advanced Versa HD System to Begin Treating Cancer Patients at New Swiss Radiotherapy Clinic
7. Krebspatienten an neuem Schweizer Zentrum für Strahlentherapie werden mit Elektas fortschrittlichem Versa HD-System behandelt
8. Denmarks Odense University Hospital Orders Elektas New Versa HD Linear Accelerator for Radiotherapy Treatment of Patients with Cancer
9. Elekta Focuses on Clinical Workflows with MOSAIQ Oncology Information Management System at HIMSS13 Meeting
10. Banner MD Anderson Cancer Center Acquires Multiple Elekta Cancer Management Systems
11. Elektas New Radiation Oncology Technology to Shape the Future of Cancer Care
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Building on its ... & Johnson (NYSE: JNJ ) today announced ... Companies to significantly reduce the burden of HIV ... 74 percent of new HIV infections among adolescents ... AIDS Day, these new initiatives include collaborations with ...
(Date:12/1/2015)... 2015 ) ... Equipment and Disposables Market by product, by Animal ... their offering. --> ) has ... and Disposables Market by product, by Animal - ... offering. --> Research and Markets ( ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a ... number even greater among Millennials (a whopping one in three aged 18 to 25 ... who are dissatisfied with their ink. In fact, RealSelf , the world’s largest ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch ... product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
Breaking Medicine News(10 mins):